Freestone Grove Partners LP Travere Therapeutics, Inc. Transaction History
Freestone Grove Partners LP
- $8.16 Trillion
- Q4 2024
A detailed history of Freestone Grove Partners LP transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Freestone Grove Partners LP holds 25,521 shares of TVTX stock, worth $595,404. This represents 0.01% of its overall portfolio holdings.
Number of Shares
25,521Holding current value
$595,404% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding TVTX
# of Institutions
213Shares Held
94.1MCall Options Held
1.2MPut Options Held
778K-
Black Rock Inc. New York, NY7.64MShares$178 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY7.36MShares$172 Million1.81% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.74MShares$157 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD4.97MShares$116 Million3.46% of portfolio
-
Macquarie Group LTD Australia, C34.26MShares$99.4 Million0.09% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $1.5B
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...